The reauthorizations of generic and biosimilar user-fee programs GDUFA and BsUFA bring opportunities and progress for the US off-patent sector, industry association the AAM believes.
The reauthorizations of generic and biosimilar user-fee programs GDUFA and BsUFA bring opportunities and progress for the US off-patent sector, industry association the AAM believes.